

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Chronic lymphocytic leukemia (CLL)	Receptor tyrosine kinase-like orphan receptor 1 (ROR1)	<p>Mouse studies suggest inhibiting ROR1 could help treat CLL. In transgenic mice expressing human <i>ROR1</i> and <i>T cell leukemia/lymphoma 1A (TCL1A)</i> in B cells, CLL-like disease developed earlier than that in transgenic mice expressing either human gene alone. In <i>ROR1</i> transgenic mice engrafted with leukemia cells expressing ROR1 alone or in combination with TCL1A, an antibody targeting human ROR1 decreased leukemic cell engraftment compared with IgG control. Ongoing studies include developing a humanized antibody targeting ROR1.</p> <p>Kancera AB has a ROR1 inhibitor in discovery to treat CLL.</p> <p>SciBX 7(4); doi:10.1038/scibx.2014.115 Published online Jan. 30, 2014</p>	Patent application filed; available for licensing	<p>Widhopf II, G.F. <i>et al. Proc. Natl. Acad. Sci. USA</i>; published online Dec. 30, 2013; doi:10.1073/pnas.1308374111</p> <p>Contact: Thomas J. Kipps, University of California, San Diego, La Jolla, Calif. e-mail: tkipps@ucsd.edu</p>